GlycanAge Conference Aims to Bring Inflammaging Tests Into Clinical Practice
GlycanAge's Dubrovnik conference targets translating 25 years of inflammaging research into real clinical tools for doctors and patients.
Summary
GlycanAge, a biological age-testing company, is hosting a landmark conference in Dubrovnik this June to push inflammaging science into everyday medicine. Co-organized with Mayo Clinic, the event brings together leading scientists and clinicians to explore how glycan biomarkers in blood can detect chronic low-grade inflammation years before disease appears. GlycanAge claims its glycan analysis can identify risk patterns up to a decade before conditions like diabetes, heart attack, or stroke become symptomatic. With data from over 300,000 people and operations across 64 markets, the company is positioning its tool as clinically grade-ready. The conference marks a potential turning point in shifting longevity medicine from reactive treatment toward early, preventive intervention.
Detailed Summary
Chronic low-grade inflammation — dubbed inflammaging — has been studied for 25 years as a silent driver of aging and age-related disease. Now, biotech company GlycanAge is pushing to move that science out of academic journals and into clinical practice, hosting a landmark conference in Dubrovnik, Croatia this June co-organized with Mayo Clinic under the ISABS conference series.
At the heart of GlycanAge's approach are glycans, sugar molecules attached to proteins that act as molecular switches regulating immune behavior. By analyzing glycan profiles in blood, the company claims it can detect whether a person's biology is trending toward inflammation or protection — potentially up to 10 years before conditions like diabetes, heart disease, or stroke become clinically apparent. CEO Nikolina Lauc states the measurement exceeds clinical-grade standards.
The conference will feature inflammaging pioneer Professor Claudio Franceschi and dedicate a full day to clinical application — how doctors can actually use these insights with patients. This is significant because most longevity biomarkers remain in a wellness gray zone, scientifically interesting but not integrated into medical systems. GlycanAge is explicitly positioning itself on the clinical side of that divide.
The company has analyzed glycan profiles from over 300,000 individuals, contributed to hundreds of peer-reviewed publications, and now operates across 64 markets with roughly 2,000 clinic partners. That scale lends some credibility to its claims, though independent validation in diverse populations remains an important benchmark.
The practical implication is a potential shift in healthcare logic — from treating illness after it arrives to anticipating and preventing it years earlier through biological monitoring. For health-conscious individuals, this raises the prospect of actionable lifestyle interventions guided by inflammation biomarkers long before symptoms emerge. Key caveats include whether clinical adoption will follow conference enthusiasm and how patients psychologically handle early risk information.
Key Findings
- Glycan biomarkers may detect diabetes, heart attack, and stroke risk up to 10 years before symptoms appear.
- GlycanAge has analyzed over 300,000 glycan profiles and contributed to hundreds of peer-reviewed studies.
- The June conference, co-organized with Mayo Clinic, focuses specifically on translating inflammaging science into clinical tools.
- Inflammaging — chronic low-grade inflammation accelerating aging — is a 25-year-old concept now deemed ready for clinical application.
- GlycanAge operates across 64 markets with ~2,000 clinic partners, suggesting meaningful real-world clinical integration already underway.
Methodology
This is a news report from Longevity.Technology covering a company-hosted conference announcement. Evidence basis is largely company claims and executive quotes rather than newly published peer-reviewed data. Independent clinical validation of GlycanAge's 10-year predictive claims is not detailed in the article.
Study Limitations
The article relies heavily on company statements and lacks citation of specific peer-reviewed studies supporting the 10-year predictive claim. Independent replication in diverse populations is not addressed. Readers should consult primary literature and await post-conference clinical guidelines before drawing firm conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.